By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


GenSight Biologics 

Paris      France
Phone: +33-1-7621-7220 Fax: n/a


Company News
GenSight Biologics Receives Approval To Include Teenage Patients In RESCUE And REVERSE Phase III Trials With GS010 In Leber’s Hereditary Optic Neuropathy 9/8/2016 11:06:52 AM
GenSight Biologics Receives Orphan Drug Designation And Advanced Therapy Medicinal Product Classification In Europe For GS030 In Retinitis Pigmentosa 9/1/2016 1:08:31 PM
GenSight Biologics Announces Additional Promising Results Of Its Phase I/II Study With GS010 For The Treatment Of Leber’s Hereditary Optic Neuropathy (LHON) 6/8/2016 8:53:21 AM
GenSight Biologics Closes $36 Million Series B Funding Round 7/23/2015 6:08:51 AM
Eye Sees More Gene Therapy: GenSight Biologics Files For A $100 Million IPO 7/10/2015 10:01:40 AM
GenSight Biologics Appoints Thomas Gidoin As Chief Financial Officer & Michael Wyzga To Board Of Directors 7/7/2015 10:07:16 AM
GenSight Biologics, Pixium Vision And Fondation Voir Et Entendre Join Forces And Benefit From A Total € 18.5 Million Funding For SIGHT AGAIN As Part Of The Investment For The Future 1/7/2015 8:39:54 AM